$19.58
4.37% yesterday
Nasdaq, Oct 30, 09:05 pm CET
ISIN
BMG762791017
Symbol
ROIV

Roivant Sciences Stock price

$19.58
+4.45 29.41% 1M
+7.96 68.50% 6M
+7.75 65.51% YTD
+7.80 66.21% 1Y
+14.44 280.93% 3Y
+9.66 97.38% 5Y
+9.66 97.38% 10Y
+9.66 97.38% 20Y
Nasdaq, Closing price Thu, Oct 30 2025
+0.82 4.37%
ISIN
BMG762791017
Symbol
ROIV
Industry

Key metrics

Basic
Market capitalization
$13.4b
Enterprise Value
$8.9b
Net debt
positive
Cash
$4.5b
Shares outstanding
682.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
575.6 | 576.9
EV/Sales
381.7 | 382.6
EV/FCF
negative
P/B
3.1
Financial Health
Equity Ratio
86.2%
Return on Equity
-3.7%
ROCE
-24.1%
ROIC
-241.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$23.2m | $23.2m
EBITDA
$-1.2b | $-1.2b
EBIT
$-1.2b | $-1.1b
Net Income
$-490.6m | $-984.2m
Free Cash Flow
$-858.7m
Growth (TTM | estimate)
Revenue
-79.1% | -20.2%
EBITDA
-15.1% | -8.9%
EBIT
-13.8% | -2.3%
Net Income
-110.4% | -472.3%
Free Cash Flow
-20.9%
Margin (TTM | estimate)
Gross
96.3%
EBITDA
-5,060.5% | -5,164.7%
EBIT
-5,104.7%
Net
-2,111.8% | -4,246.5%
Free Cash Flow
-3,695.9%
More
EPS
$-0.7
FCF per Share
$-1.3
Short interest
5.0%
Employees
750
Rev per Employee
$40.0k
Show more

Is Roivant Sciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.

Roivant Sciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Roivant Sciences forecast:

16x Buy
89%
2x Hold
11%

Analyst Opinions

18 Analysts have issued a Roivant Sciences forecast:

Buy
89%
Hold
11%

Financial data from Roivant Sciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
23 23
79% 79%
100%
- Direct Costs 0.85 0.85
93% 93%
4%
22 22
78% 78%
96%
- Selling and Administrative Expenses 626 626
1% 1%
2,693%
- Research and Development Expense 583 583
14% 14%
2,509%
-1,176 -1,176
15% 15%
-5,061%
- Depreciation and Amortization 10 10
51% 51%
44%
EBIT (Operating Income) EBIT -1,186 -1,186
14% 14%
-5,105%
Net Profit -491 -491
110% 110%
-2,112%

In millions USD.

Don't miss a Thing! We will send you all news about Roivant Sciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Roivant Sciences Stock News

Neutral
GlobeNewsWire
4 days ago
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2025.
Neutral
GlobeNewsWire
4 days ago
BASEL, Switzerland and LONDON and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Monday, November 10, 2025, to report its financial results for the second quarter ended September 30, 2025, and provide a business update.
Neutral
Seeking Alpha
about one month ago
Roivant Sciences Ltd. (NASDAQ:ROIV ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 1:58 PM EDT Company Participants Matthew Gline - CEO & Director Presentation Unknown Analyst I cover U.S. biotech at Bernstein.
More Roivant Sciences News

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Head office Bermuda
CEO Matthew Gline
Employees 750
Founded 2014
Website roivant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today